Evercore ISI Group maintains Stryker at Outperform, lowers price target to $320 from $335

What happened

Evercore ISI Group kept its Outperform rating on Stryker but lowered its price target to $320 from $335, a 4.5% decrease. The new target implies 2.6% upside from the October 29 close of $311.75.

Confirmed

Global impact / market context

A lower price target still above the current share price suggests Evercore expects modest gains but less than before. For investors, this means the firm trimmed its expectations for Stryker's stock while keeping a positive rating on the medical device company.

Analyst inference

Other recent analyst notes on Stryker show price targets from $304 to $375, with ratings ranging from Hold to Overweight. Evercore's $320 target sits near the lower end of that range, which suggests it is less optimistic than several peers.

Analyst inference

What to watch

1. Five recent analyst notes on Stryker have price targets ranging from $304 to $375, with ratings from Hold to Overweight, showing a wide spread of views on the stock. Confirmed
2. Investors could compare Evercore's $320 target and Outperform rating with future analyst updates, since changes in ratings or targets may shift how the stock is viewed. Proposed
3. If more analysts lower their Stryker price targets, that could signal weaker expected profit growth and weigh on the stock, while upgrades or higher targets could support it. Analyst inference

Evidence

• Original source link unavailable